FDA
-
-
-
-
-
-
-
Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
-
-
-
-
-
-
-
Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio
-
-
-
-
-
-
-
EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

